SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: FNS who wrote (676)5/28/1998 4:32:00 PM
From: sol dude  Read Replies (1) | Respond to of 965
 
To All,
CNBC says panel recommends approval for avakine

soldude



To: FNS who wrote (676)5/28/1998 4:51:00 PM
From: PawPr  Read Replies (1) | Respond to of 965
 
I think IMNX's drug is the same as CNTO, but CNTO did its testing first on Crohn's, then on RA, whereas IMNX went straight to RA. ( Our afternoon monsoon has finally stopped, so off I go to work out. You'll hear from me when I return if any news has been posted ).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News